Developed by Eli Lilly and Company, it simultaneously targets GLP-1, GIP, and glucagon receptors a mechanism that distinguishes it from currently approved therapies such as semaglutide and tirzepatide
Sci Rep (2017) 7(1):8933
The findings indicate that, despite specific degradation during digestion, a significant proportion of polyphenols and their metabolites remain sufficiently stable for absorption, hence facilitating their potential health-promoting effects in living organisms post-absorption
17 HACK POINTS earned on this product worth $0.34 250 HACK POINTS per referral ($5.00) + friend gets 16% off LEADERBOARD Top referrers unlock exclusive perks and featured status
This discrepancy raised alarm bells and prompted a thorough investigation
Harkavyi A, Abuirmeileh A, Lever R, Kingsbury AE, Biggs CS, Whitton PS